Entering text into the input field will update the search result below

Tango's TNG908 cancer program cleared for phase 1/2 trial; provides pipeline update

Jan. 24, 2022 8:07 AM ETTango Therapeutics, Inc. (TNGX) StockBy: Ravikash Bakolia, SA News Editor

Doctor doing research in lab during COVID-19

Morsa Images/DigitalVision via Getty Images

  • Tango Therapeutics (NASDAQ:TNGX)'s investigational new drug (IND) application for TNG908 was cleared by the U.S. Food and Drug Administration (FDA) to begin a phase 1/2 trial in certain types of cancers in H1 2022.

Recommended For You

More Trending News

About TNGX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
TNGX--
Tango Therapeutics, Inc.